Compare Impinj Inc (PI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Summit Therapeutics Inc — how do they compare? Impinj Inc trades at $189.56 (market cap $5.60B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× Impinj Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Summit Therapeutics Inc for 16 Days on average.
| PI | SMMT | |
|---|---|---|
Market Cap | $5.60B | $13.71B |
Volume | 9,929 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $241.91 | $26.38 |
52-Week Low | $91.34 | $12.43 |
Typical Hold Time | 22 Days | 16 Days |
Enterprise Value | $5.73B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $189.16, down 0.98% on the day, with strong analyst support (16 buy ratings, 0 sell) and a consensus price target of $178.83. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though profitability remains negative with a -7.26% net income margin. Recent news highlights include upcoming Q3 earnings and CFO stock sales.
While technical indicators and analyst sentiment are positive, fundamental challenges persist with negative ROE and high valuation multiples. The company's RAIN RFID technology presents growth opportunities in logistics, but investors should weigh execution risks against the bullish consensus.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
